Home›Companies›Biotech & Pharma›AirNexis

AirNexis Therapeutics, Inc.

Develops an inhaled treatment for people with chronic obstructive pulmonary disease.

Updated Nov 11, 2026·Latest SEC filing Mar 9, 2026·Suggest an edit

About AirNexis

AirNexis is a private company based in Palo Alto, California, incorporated in 2024 in Delaware. It has reported $62,000,000 raised in one offering on Form D since March 2026. Its chief executive is Maria Fardis.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 9, 2026Mar 9, 2026$62,000,000of $200.0M target13$4.7MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on AirNexis's Form D filed Mar 9, 2026.

Anna Chen
Anna Chen
Board Member
Evan Caplan
Evan Caplan
Board Member
JL
James Li
Chair of the Board
Jill Carroll
Jill Carroll
Board Member
Maria Fardis
Maria Fardis
CEO and director
Also a director at Quanta Therapeutics.

Sources

  1. SECAirNexis Therapeutics, Inc. filing history
  2. CompanyAirNexis privacy policy
  3. CompanyAirNexis about